THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, August 09, 2021
Syneos Health and Aetion partner to provide analytics-driven solutions for drug development and better patient outcomes.
FREMONT, CA: Syneos Health® and Aetion® announce a partnership to provide regulatory-grade data and analytics-driven solutions to advance drug development and improve patient outcomes. The partnership brings together SyneosHealth's proprietary data collection and research solutions with Aetion Evidence Platform® (AEP) to produce evidence through patient data curation and real-world data.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
SyneosHealth's offerings, including its Biopharmaceutical Acceleration Model®, Dynamic Assembly®, and RWE Solutions, enable biopharmaceutical companies to incite product development and patient access to new therapies, diminish risk with evidence-based decision-making, and prove value to a broad healthcare ecosystem, including patients, regulators, payers, and health care providers. Aetion's AEP examines data from the real world, including claims, electronic health records, registries, and clinical trial data, to produce transparent, rapid, and scientifically validated real-world evidence on the safety, effectiveness, and value of medical interventions.
“Today’s dynamic healthcare landscape is challenging the product development process as regulatory authorities and payers demand faster and greater proof of value for therapies, and improved outcomes for patients,” said Christian Tucat, President, Syneos One and Real World Evidence for Syneos Health. “Integrating Syneos Health and Aetions solutions drives quality, transparency, and speed in the use of patient-level data by leveraging Aetions strong analytics platform and capabilities. This places the patient closer to the center of research, unlocking efficiencies across development and commercialization, speeding patient access, and maximizing the return on investment for our customers.”
“Aetion is becoming the partner of choice for organizations committed to the highest standards of scientific rigor for creating RWE,” said Carolyn Magill, CEO of Aetion. “By bringing together SyneosHealths deep expertise in trial design and data collection, and our scientifically validated RWE platform, we are providing an end-to-end solution to generate evidence that can be trusted by health care stakeholders.”
Aetion will be an integral partner in the Syneos Health Dynamic Assembly network, an open ecosystem of preferred, best-in-class data and technology collaborators engaged in producing fit-for-purpose solutions to address the nuances of each customer engagement strategically.
More in News